Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 138   

Articles published

GSK 1,475.58 +15.58 (1.07%)
price chart
Better buy: GlaxoSmithKline plc vs Shire plc
On the face of it, GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP) are both very similar; large, globe-spanning pharmaceutical companies with cutting-edge treatments for a range of diseases.
GlaxoSmithKline plc 23.5% Potential Upside Indicated by JP Morgan Cazenove
GlaxoSmithKline plc using EPIC/TICKER code LON:GSK has had its stock rating noted as 'Retains' with the recommendation being set at 'NEUTRAL' this morning by analysts at JP Morgan Cazenove.
The Goldman Sachs Group Inc. Reiterates “Buy” Rating for GlaxoSmithKline PLC ...  DailyQuint
Important Rating: Professional Analysts at JP Morgan Cazenove Didn't ...  Thorold News
GSK Stock: GlaxoSmithKline PLC Is a High-Dividend Stock
One sector that is known for large gross margins is the healthcare sector. Typically, high-gross-margin businesses are not looked at by dividend investors, the reason being that there is often no dividend.
GlaxoSmithKline PLC (LON:GSK) Receives 'Buy' Rating From Brokers At ...  UK Market News
Rating Change: GlaxoSmithKline PLC (LON:GSK) Investors: Jefferies ...  Thorold News
Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
During most of 2016, when shares of AbbVie (NYSE:ABBV) went up, so did shares of GlaxoSmithKline (NYSE:GSK). However, after the U.S.
Market Fallers: Fresnillo Plc, GKN plc, Glencore PLC, GlaxoSmithKline plc
The share price for Fresnillo Plc company symbol: LON:FRES has declined -4.17% or -50 points during today's session so far.
GlaxoSmithKline plc (GSK) Given "Buy" Rating at Goldman Sachs ...  Community Financial News
Today: GlaxoSmithKline plc (GSK) PT Raised to GBX 1950 at Jefferies Group  DailyQuint
Trade Report: The Poplar Forest Capital LLC Reached $360000 position of ...
Poplar Forest Capital LLC maintained its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC).
Traders See Bearish Options Activity GlaxoSmithKline plc (ADR)  Frisco Fastball
ABR Of GlaxoSmithKline PLC (NYSE:GSK) At 1.86  Stock Observer
How GlaxoSmithKline plc's first-mover advantage could power future profits
Today, eighteen months earlier than planned, GlaxoSmithKline(LSE: GSK) announced the filing of a regulatory submission with the US Food and Drug Administration for the firm's new three-in-one lung drug.
GlaxoSmithKline PLC files closed triple therapy for COPD in US  DirectorsTalk Interviews
GlaxoSmithKline and Innoviva celebrate early FDA submission of COPD treatment  Proactive Investors UK
Today's Market Runner: GlaxoSmithKline plc (ADR) Can't Be More Risky. Just ...
The stock of GlaxoSmithKline plc (ADR) (NYSE:GSK) hit a new 52-week low and has $35.07 target or 6.00% below today's $37.31 share price.
GlaxoSmithKline plc's (GSK) "Neutral" Rating Reaffirmed at ...  The Cerbat Gem
GlaxoSmithKline plc's (GSK): Market Traders Alert  Hot Stocks Point
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar� Ellipta� (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various ...
GSK Files Regulatory Submission In EU For Triple Combination Therapy On COPD  Nasdaq
TOP NEWS: Glaxo's Relvar Ellipta Approved For COPD In Japan  London South East (registration) (blog)
Worth Watching Stocks:, inc. (NYSE:CRM), GlaxoSmithKline plc ... is the market and technology leader in on-demand business services. The company's Salesforce suite of on-demand CRM applications allows customers to manage and share all of their sales, support, marketing and partner information ...